Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shanghai Haohai Biological Technology Co., Ltd. Class H ( (HK:6826) ) has provided an announcement.
Shanghai Haohai Biological Technology Co., Ltd. has announced a connected transaction involving the acquisition of a 22.2554% equity interest in Jiangxi Ruiji Bio-engineering Technology Co., Ltd. The acquisition will be executed in stages between 2025 and 2026, with Shanghai Haohai acquiring approximately 19.8000% and a co-buyer acquiring 2.4554%. The transaction, valued at RMB43,107,466.41, is subject to reporting and announcement requirements under the Hong Kong Listing Rules, but is exempt from circular and independent shareholders’ approval.
The most recent analyst rating on (HK:6826) stock is a Buy with a HK$30.00 price target. To see the full list of analyst forecasts on Shanghai Haohai Biological Technology Co., Ltd. Class H stock, see the HK:6826 Stock Forecast page.
More about Shanghai Haohai Biological Technology Co., Ltd. Class H
Shanghai Haohai Biological Technology Co., Ltd. is a company incorporated in the People’s Republic of China, operating in the biotechnology industry. The company focuses on the development and commercialization of biological products and technologies.
Average Trading Volume: 245,912
Technical Sentiment Signal: Sell
Current Market Cap: HK$11.14B
For detailed information about 6826 stock, go to TipRanks’ Stock Analysis page.